Navigation Links
Cell Therapeutics, Inc. (CTI) to Present at 11th Annual BIO CEO & Investor Conference
Date:1/26/2009

SEATTLE, Jan. 26 /PRNewswire-FirstCall/ -- Cell Therapeutics, Inc. (CTI) (Nasdaq and MTA: CTIC) management will present at the 11th Annual BIO CEO & Investor Conference on Tuesday, February 10th at 9:30 AM in the Jade Room of the Waldorf-Astoria Hotel.

The presentation will also be webcast live with slides, and available for replay after the presentation. The webcast can be accessed at http://www.celltherapeutics.com.

                        BIO CEO & Investor Conference
                 CTI Presentation: Tuesday, February 10, 2009
           9:30 AM Eastern/3:30 PM Central European/6:30 AM Pacific
                       Jade Room, Waldorf-Astoria Hotel
         Audio webcast with slides athttp://www.celltherapeutics.com

     Media Contact:                                 Investors Contact:
     Cell Therapeutics, Inc.                        Cell Therapeutics, Inc.
     Dan Eramian                                    Ed Bell
     T: 206.272.4343                                T: 206.272.4345
     F: 206.272.4434                                Lindsey Jesch Logan
     E: media@ctiseattle.com                        T: 206.272.4347
    http://www.celltherapeutics.com/press_room     F: 206.272.4434
                                                    E: invest@ctiseattle.com
                                    http://www.celltherapeutics.com/investors

'/>"/>
SOURCE Cell Therapeutics, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1

Related biology technology :

1. Cell Therapeutics, Inc. Provides Update on the Special Meeting of Shareholders
2. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $32.65 Million of Senior Convertible Notes
3. Webcast Alert: Regulus Therapeutics, Alnylam Pharmaceuticals and Isis Pharmaceuticals Announce New Nature Publication on miR-21 Conference Call
4. Cell Therapeutics, Inc. (CTI) Zevalin Joint Venture Conference Call to be Webcast with Slides
5. Cell Therapeutics, Inc. (CTI) to Discuss Zevalin Joint Venture with Spectrum Pharmaceuticals
6. Cell Therapeutics, Inc. (CTI) to Report 2008 Third Quarter Financial Results on November 7
7. Laureate Pharma Announces Agreement with Tolera Therapeutics, Inc.
8. Tobira Therapeutics, Inc. to Present at the 2008 BIO Investor Forum
9. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $24.7 Million of Senior Convertible Notes
10. Cell Therapeutics, Inc. (CTI) to Present at Three Upcoming Investor Conferences
11. Cell Therapeutics, Inc. Announces Single Institutional Investor Purchases $14.2 Million of Senior Convertible Notes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/18/2017)... ... February 17, 2017 , ... The BMT Tandem Meetings of ... International Blood & Marrow Transplant Research (CIBMTR) will take place Feb. 22-26, 2017 ... combined scientific sessions offer investigators, clinicians, laboratory technicians, clinical research professionals, nurses, pharmacists, ...
(Date:2/17/2017)... 17, 2017  If only one in every ... mutation-conferring resistance to chemotherapy, thousands of cancer cells ... focused on finding these mutations in ever-smaller subpopulations ... tumor DNA in blood — to guide treatment ... Unfortunately, however, detecting these genetic anomalies may ...
(Date:2/16/2017)... Feb. 16, 2017  ImMAGE Biotherapeutics (OTCMKTS: IMMG), an early-stage ... find a better treatment for triple negative breast cancer (TNBC), ... France program. The YEi Start ... designed to help entrepreneurs grow their business in ... eight American companies selected to complete an intensive one week ...
(Date:2/16/2017)... Feb. 16, 2017   Capricor Therapeutics, Inc. ... biotechnology company developing first-in-class biological therapies for cardiac ... has elected to terminate its license agreement with ... agonists, including Cenderitide. "Our decision to ... we prioritize our efforts to advance our core ...
Breaking Biology Technology:
(Date:2/2/2017)... , Feb. 2, 2017   TapImmune, ... clinical-stage immuno-oncology company specializing in the development of ... the treatment of cancer and metastatic disease, announced ... and GMP manufacturing of a second clinical lot ... targeting folate receptor alpha. The manufactured vaccine product ...
(Date:1/31/2017)... CAMBRIDGE, Mass. , Jan. 31, 2017 /PRNewswire-USNewswire/ ... develop novel therapies for the treatment of bacterial ... generation set of antibacterial candidates from Pro Bono ... the increased prevalence of multi-drug resistant forms of ... by Cantab Anti Infectives Ltd, a PBB group ...
(Date:1/25/2017)... YORK , Jan. 25, 2017 The ... Access Management (IAM) lifecycle is comprised of a ... for the purpose of maintaining digital identities and ... resources and applications. There are significant number of ... from time to time by optimizing processes and ...
Breaking Biology News(10 mins):